Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity

Wenjie Yin, Dorothee Duluc, HyeMee Joo, Yaming Xue, Chao Gu, Zhiqing Wang, Lei Wang, Richard Ouedraogo, Lance Oxford, Amelia Clark, Falguni Parikh, Seunghee Kim-Schulze, Lu Ann Thompson-Snipes, Sang Yull Lee, Clay Beauregard, Jung Hee Woo, Sandra Zurawski, Andrew G. Sikora, Gerard Zurawski, SangKon Oh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Human papillomavirus (HPV), particularly HPV16 and HPV18, can cause cancers in diverse anatomical sites, including the anogenital and oropharyngeal (throat) regions. Therefore, development of safe and clinically effective therapeutic vaccines is an important goal. Herein, we show that a recombinant fusion protein of a humanized antibody to CD40 fused to HPV16.E6/7 (αCD40-HPV16.E6/7) can evoke HPV16.E6/7-specific CD8+ and CD4+ T-cell responses in head-and-neck cancer patients in vitro and in human CD40 transgenic (hCD40Tg) mice in vivo. The combination of αCD40-HPV16.E6/7 and poly(I:C) efficiently primed HPV16. E6/7-specific T cells, particularly CD8+ T cells, in hCD40Tg mice. Inclusion of montanide enhanced HPV16.E6/7-specific CD4+, but not CD8+, T-cell responses. Poly(I:C) plus αCD40-HPV16.E6/7 was sufficient to mount both preventative and therapeutic immunity against TC-1 tumors in hCD40Tg mice, significantly increasing the frequency of HPV16-specific CD8+ CTLs in the tumors, but not in peripheral blood. In line with this, tumor volume inversely correlated with the frequency of HPV16.E6/7-specific CD8+ T cells in tumors, but not in blood. These data suggest that CD40-targeting vaccines for HPV-associated malignancies can provide a highly immunogenic platform with a strong likelihood of clinical benefit. Data from this study offer strong support for the development of CD40-targeting vaccines for other cancers in the future.

Original languageEnglish (US)
Pages (from-to)823-834
Number of pages12
JournalCancer immunology research
Volume4
Issue number10
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Papillomavirus Vaccines
Cancer Vaccines
Immunity
T-Lymphocytes
Transgenic Mice
Neoplasms
Recombinant Fusion Proteins
Therapeutics
Antibodies, Monoclonal, Humanized
Head and Neck Neoplasms
Pharynx
Tumor Burden
Vaccines

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity. / Yin, Wenjie; Duluc, Dorothee; Joo, HyeMee; Xue, Yaming; Gu, Chao; Wang, Zhiqing; Wang, Lei; Ouedraogo, Richard; Oxford, Lance; Clark, Amelia; Parikh, Falguni; Kim-Schulze, Seunghee; Thompson-Snipes, Lu Ann; Lee, Sang Yull; Beauregard, Clay; Woo, Jung Hee; Zurawski, Sandra; Sikora, Andrew G.; Zurawski, Gerard; Oh, SangKon.

In: Cancer immunology research, Vol. 4, No. 10, 01.10.2016, p. 823-834.

Research output: Contribution to journalArticle

Yin, W, Duluc, D, Joo, H, Xue, Y, Gu, C, Wang, Z, Wang, L, Ouedraogo, R, Oxford, L, Clark, A, Parikh, F, Kim-Schulze, S, Thompson-Snipes, LA, Lee, SY, Beauregard, C, Woo, JH, Zurawski, S, Sikora, AG, Zurawski, G & Oh, S 2016, 'Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity', Cancer immunology research, vol. 4, no. 10, pp. 823-834. https://doi.org/10.1158/2326-6066.CIR-16-0128
Yin, Wenjie ; Duluc, Dorothee ; Joo, HyeMee ; Xue, Yaming ; Gu, Chao ; Wang, Zhiqing ; Wang, Lei ; Ouedraogo, Richard ; Oxford, Lance ; Clark, Amelia ; Parikh, Falguni ; Kim-Schulze, Seunghee ; Thompson-Snipes, Lu Ann ; Lee, Sang Yull ; Beauregard, Clay ; Woo, Jung Hee ; Zurawski, Sandra ; Sikora, Andrew G. ; Zurawski, Gerard ; Oh, SangKon. / Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity. In: Cancer immunology research. 2016 ; Vol. 4, No. 10. pp. 823-834.
@article{6f202f5f0bf943e5848372333e1a5c2a,
title = "Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity",
abstract = "Human papillomavirus (HPV), particularly HPV16 and HPV18, can cause cancers in diverse anatomical sites, including the anogenital and oropharyngeal (throat) regions. Therefore, development of safe and clinically effective therapeutic vaccines is an important goal. Herein, we show that a recombinant fusion protein of a humanized antibody to CD40 fused to HPV16.E6/7 (αCD40-HPV16.E6/7) can evoke HPV16.E6/7-specific CD8+ and CD4+ T-cell responses in head-and-neck cancer patients in vitro and in human CD40 transgenic (hCD40Tg) mice in vivo. The combination of αCD40-HPV16.E6/7 and poly(I:C) efficiently primed HPV16. E6/7-specific T cells, particularly CD8+ T cells, in hCD40Tg mice. Inclusion of montanide enhanced HPV16.E6/7-specific CD4+, but not CD8+, T-cell responses. Poly(I:C) plus αCD40-HPV16.E6/7 was sufficient to mount both preventative and therapeutic immunity against TC-1 tumors in hCD40Tg mice, significantly increasing the frequency of HPV16-specific CD8+ CTLs in the tumors, but not in peripheral blood. In line with this, tumor volume inversely correlated with the frequency of HPV16.E6/7-specific CD8+ T cells in tumors, but not in blood. These data suggest that CD40-targeting vaccines for HPV-associated malignancies can provide a highly immunogenic platform with a strong likelihood of clinical benefit. Data from this study offer strong support for the development of CD40-targeting vaccines for other cancers in the future.",
author = "Wenjie Yin and Dorothee Duluc and HyeMee Joo and Yaming Xue and Chao Gu and Zhiqing Wang and Lei Wang and Richard Ouedraogo and Lance Oxford and Amelia Clark and Falguni Parikh and Seunghee Kim-Schulze and Thompson-Snipes, {Lu Ann} and Lee, {Sang Yull} and Clay Beauregard and Woo, {Jung Hee} and Sandra Zurawski and Sikora, {Andrew G.} and Gerard Zurawski and SangKon Oh",
year = "2016",
month = "10",
day = "1",
doi = "10.1158/2326-6066.CIR-16-0128",
language = "English (US)",
volume = "4",
pages = "823--834",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity

AU - Yin, Wenjie

AU - Duluc, Dorothee

AU - Joo, HyeMee

AU - Xue, Yaming

AU - Gu, Chao

AU - Wang, Zhiqing

AU - Wang, Lei

AU - Ouedraogo, Richard

AU - Oxford, Lance

AU - Clark, Amelia

AU - Parikh, Falguni

AU - Kim-Schulze, Seunghee

AU - Thompson-Snipes, Lu Ann

AU - Lee, Sang Yull

AU - Beauregard, Clay

AU - Woo, Jung Hee

AU - Zurawski, Sandra

AU - Sikora, Andrew G.

AU - Zurawski, Gerard

AU - Oh, SangKon

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Human papillomavirus (HPV), particularly HPV16 and HPV18, can cause cancers in diverse anatomical sites, including the anogenital and oropharyngeal (throat) regions. Therefore, development of safe and clinically effective therapeutic vaccines is an important goal. Herein, we show that a recombinant fusion protein of a humanized antibody to CD40 fused to HPV16.E6/7 (αCD40-HPV16.E6/7) can evoke HPV16.E6/7-specific CD8+ and CD4+ T-cell responses in head-and-neck cancer patients in vitro and in human CD40 transgenic (hCD40Tg) mice in vivo. The combination of αCD40-HPV16.E6/7 and poly(I:C) efficiently primed HPV16. E6/7-specific T cells, particularly CD8+ T cells, in hCD40Tg mice. Inclusion of montanide enhanced HPV16.E6/7-specific CD4+, but not CD8+, T-cell responses. Poly(I:C) plus αCD40-HPV16.E6/7 was sufficient to mount both preventative and therapeutic immunity against TC-1 tumors in hCD40Tg mice, significantly increasing the frequency of HPV16-specific CD8+ CTLs in the tumors, but not in peripheral blood. In line with this, tumor volume inversely correlated with the frequency of HPV16.E6/7-specific CD8+ T cells in tumors, but not in blood. These data suggest that CD40-targeting vaccines for HPV-associated malignancies can provide a highly immunogenic platform with a strong likelihood of clinical benefit. Data from this study offer strong support for the development of CD40-targeting vaccines for other cancers in the future.

AB - Human papillomavirus (HPV), particularly HPV16 and HPV18, can cause cancers in diverse anatomical sites, including the anogenital and oropharyngeal (throat) regions. Therefore, development of safe and clinically effective therapeutic vaccines is an important goal. Herein, we show that a recombinant fusion protein of a humanized antibody to CD40 fused to HPV16.E6/7 (αCD40-HPV16.E6/7) can evoke HPV16.E6/7-specific CD8+ and CD4+ T-cell responses in head-and-neck cancer patients in vitro and in human CD40 transgenic (hCD40Tg) mice in vivo. The combination of αCD40-HPV16.E6/7 and poly(I:C) efficiently primed HPV16. E6/7-specific T cells, particularly CD8+ T cells, in hCD40Tg mice. Inclusion of montanide enhanced HPV16.E6/7-specific CD4+, but not CD8+, T-cell responses. Poly(I:C) plus αCD40-HPV16.E6/7 was sufficient to mount both preventative and therapeutic immunity against TC-1 tumors in hCD40Tg mice, significantly increasing the frequency of HPV16-specific CD8+ CTLs in the tumors, but not in peripheral blood. In line with this, tumor volume inversely correlated with the frequency of HPV16.E6/7-specific CD8+ T cells in tumors, but not in blood. These data suggest that CD40-targeting vaccines for HPV-associated malignancies can provide a highly immunogenic platform with a strong likelihood of clinical benefit. Data from this study offer strong support for the development of CD40-targeting vaccines for other cancers in the future.

UR - http://www.scopus.com/inward/record.url?scp=84994171942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994171942&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-16-0128

DO - 10.1158/2326-6066.CIR-16-0128

M3 - Article

VL - 4

SP - 823

EP - 834

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 10

ER -